Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.
British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.
Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.
Bayer has dropped trade secrets claims against a former employee and rival company, which it had accused of stealing confidential information related to organic fungicides.
Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
The Japan Patent Office and the Intellectual Property Office of Singapore have each granted Merck KGaA a patent covering the use of paired CRISPR nickases.
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.